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are not receiving appropriate follow-up care. The cause
of these low screening rates should be examined in future
research.
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OBJECTIVE: This study evaluated the effects of 
pharmacist-managed anticoagulation monitoring services
on the clinical and economic outcomes of patients pre-
scribed warfarin therapy. 
METHODS: A retrospective chart review was conducted
for patients newly initiated with warfarin therapy
between November 1997 and April 1998. Patients used
warfarin for a minimum of 2 months and were followed
for either one-year post-initiation of warfarin usage or
until discontinuation of warfarin therapy, whichever was
earlier. Comparisons were made between the group of
patients receiving anticoagulation monitoring through
usual medical care (UMC) by their physician (“UMC
group”) and those patients enrolled in the pharmacist-
managed anticoagulation clinic (“AC patients”).
Outcome measures for the two groups include anticoag-
ulation control, incidence of warfarin adverse effects or
recurrent thromboembolic disorder, and economic evalu-
ation for inpatient and outpatient health care services 
utilized.
RESULTS: Complete data for 63 UMC patients (625
patient-months) and 18 AC patients (232 patient-months)
indicate that AC patients had better anticoagulation
control than UMC patients (51% of INRs within target
range versus 41%, respectively). However, AC patients
experienced more frequent minor recurrences (events not
requiring hospitalization) of thromboembolic disorders
or bleeding associated with warfarin (0.11 events per 
AC patient-month versus 0.08 events per UMC patient-
month). The incidence of complications that necessitated
hospitalization was similar between the two groups. The
estimated annual inpatient cost of treating the complica-
tions associated with anticoagulant therapy was $168 less
per AC patient but equivalent for both groups for out-
patient services ($348 annually). Inpatient and outpatient
charges for all medical claims for AC patients were less
than half that found for UMC patients ($241 and $405
per patient-month versus $501 and $878 per patient-
month, respectively). 
CONCLUSION: Although treatment-related complica-
tions can still occur, pharmacist-managed anticoagulation
monitoring services provided a better means of main-
taining anticoagulation control and reducing medical care
costs for patients on warfarin therapy.
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ASSESSING RISK REDUCTION AND NNT
AMONG TYPE 2 DIABETICS TREATED WITH
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OBJECTIVES: Type 2 diabetics with combined hyper-
lipidemia are at increased risk of developing coronary
heart disease (CHD). Fibrates have been shown to
improve lipid parameters; thereby, decreasing CHD risk
among treated patients. We compare fenoﬁbrate to gem-
ﬁbrozil treatment of combined hyperlipidemia in type 2
diabetics by determining the following: one year absolute
and relative risk reductions in CHD, Number Needed to
Treat (NNT) to prevent one case of CHD, and number
of CHD cases prevented. 
METHODS: In patients with lipid parameters consistent
with type 2 diabetes, absolute risk (AR) of developing
CHD in one year was determined using the Anderson car-
diovascular risk equation. Relative risk (RR) comparing
no treatment to treatment and NNT were calculated. 
The number of CHD cases prevented in one year was 
calculated from NNT and prevalence characteristics of 
a 500,000 member Medicaid population. Sensitivity
analyses were performed on age, smoking status, drug
dose, and time horizon.
RESULTS: Base case patients (60 year-old female, non-
smoker) treated with fenoﬁbrate (AR = 1.1, RR = 1.92,
NNT = 97) had lower absolute risks, more favorable 
relative risks comparing no treatment to treatment, and
required treatment of fewer patients to prevent one case
of CHD compared to gemﬁbrozil (AR = 1.5, RR = 1.42,
NNT = 157). In one year, in patients >50 years, 91 CHD
cases were prevented through the model with fenoﬁbrate
treatment, compared to 56 cases prevented with gemﬁ-
brozil. Each sensitivity analysis showed fenoﬁbrate had
the more favorable AR, RR, and NNT. For example,
using a ﬁve year time horizon on a 70 year-old smoking
male, fenoﬁbrate’s AR = 17.8, RR = 1.41, and NNT =
14, while with gemﬁbrozil’s AR = 21.0, RR = 1.20, 
and NNT = 24. In ﬁve years, 348 cases of CHD were 
prevented with fenoﬁbrate compared to 206 with 
gemﬁbrozil.
CONCLUSIONS: Fenoﬁbrate proves a better healthcare
value than gemﬁbrozil due to its superior risk reduction
and prevention of more cases of CHD.
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OBJECTIVES: The long-term beneﬁts on life expectancy
of more effective antihypertensive strategies to lower
blood pressure are not well described, particularly for
certain groups with different cardiovascular (CV) risk
factor proﬁles. We projected the life expectancy beneﬁts
of anti-hypertensive treatment strategies using a unique
primary/secondary prevention Markov Model derived
from a large epidemiologic database. 
METHODS: Longitudinal data from 57,279 middle-aged
and older male and female health professionals were
pooled to develop a primary and secondary CV event
Markov model estimating the long-term beneﬁts of anti-
hypertensive treatment based on both systolic and dias-
tolic blood pressure reduction. Seven patient states were
deﬁned: no CV event history, stroke, myocardial infarc-
tion, revascularization, non-CV death, CV death, and
history of CV event. Risk functions were developed from
gender-speciﬁc multivariate Cox proportional hazards
models for primary events, and age-adjusted models for
secondary events. The area between survival curves of 
different interventions was calculated to estimate the
incremental gains in life expectancy for the superior anti-
hypertensive treatment intervention.
RESULTS: We assumed a pre-treatment blood pressure
of 160mmHg systolic/95mmHg diastolic. We further
assumed that Strategy A yields a lowering of 20/13mm
Hg and Strategy B yields a reduction of 13/8mmHg. Post
treatment blood pressures at the start of the simulation
were thus 140/82mmHg for Strategy A and 147/87mm
Hg for Strategy B. Assuming an age of 35 years at base-
line and cycling the model for 65 years, a life expectancy
gain of 0.7 years is achieved for Strategy A versus 
Strategy B. In a diabetic population, there was a life
expectancy gain of 0.79 years for Strategy A versus 
Strategy B.
CONCLUSIONS: Substantial gains in life expectancy 
due to reduction in both primary and secondary CV
events can be achieved by superior strategies of blood
pressure lowering.
CARDIOVASCULAR DISEASES/DISORDERS—
Economic Outcomes Presentations
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OBJECTIVE: To estimate the average cost of anti-
coagulation clinic services from a provider perspective. 
METHODS: Using a retrospective cohort approach, a
random sample of 600 patients was selected from 3 geo-
graphically diverse managed care sites (N = 200 per site)
with anticoagulation clinics and followed for up to one
year. Care was provided under a traditional nurse or
pharmacist managed clinic model with most encounters
involving telephone contacts. Study patients included
adults aged 18+ years with a diagnosis of nonvalvular
atrial ﬁbrillation who received warfarin for at least 30
days. Patient contacts were evaluated based on complex-
ity (education, warfarin dose adjusted, warfarin dose not
adjusted) and the total cost of anticoagulation clinic care
was calculated for staff time, laboratory tests, and over-
head. Unit costs were estimated based on national data.
Labor costs were measured by observing the actual time
spent by clinic staff on individual patient encounters using
a prospective time study (“activity-based” approach), and
through a survey of budgeted labor hours (“budgeted-
cost” approach).
RESULTS: The average age of patients was 72 years 
and 56% were female. Approximately 85% were white.
About 75% of patients completed one year of clinic
follow-up (mean duration: 10.5 months). Patients aver-
aged 18 clinic contacts. The cost of staff time for war-
farin monitoring during follow-up was estimated to be
$91 under the activity-based approach and $176 using
the budgeted-cost approach. These costs increased to
$244 and $330 for the activity-based and budgeted-cost
approaches, respectively, once laboratory tests and over-
head were included. Average costs for patients who were
followed for a full year were $268 and $362, respectively.
While anticoagulation control was relatively similar
across sites (60% to 65% time in INR range), there was
more marked variation in costs.
CONCLUSIONS: This study provides a detailed, multi-
site assessment of the costs of warfarin monitoring using
multiple costing methodologies.
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Atrial ﬁbrillation (AF), the most common persistent
arrhythmia, increases the risk of stroke manifolds. This
risk is further enhanced in the presence of underlying 
cardiovascular diseases (CVD). Yet, the health care costs
and utilization associated with this condition have not
been well studied.
OBJECTIVE: To compare the resource utilization and
costs among patients with and without AF in an
employer-based privately insured population with under-
lying CVD. 
METHODS: Retrospective claims data from a large
group of self-insured employers were used. Patients con-
tinuously enrolled from January 1, 1996 to December 31,
